Surveillance for safety after immunization: Vaccine Adverse Event Reporting System (VAERS)--United States, 1991-2001.

Weigong Zhou(Epidemic Intelligence Service), Robert T. Chen, Susan S. Ellenberg(University of Pennsylvania), Roseanne English-Bullard, Robert Ball, John K. Iskander, Vitali Pool, Robert Pless, Penina Haber, Robert P. Wise(Center for Biologics Evaluation and Research), M. Miles Braun(Georgetown University), Gina T. Mootrey

PubMed

January 24, 2003

Cited by 397

Related Papers

Tuberculosis Associated with Infliximab, a Tumor Necrosis Factor α–Neutralizing Agent

|New England Journal of Medicine|2001|3.7k

Effects of Testosterone Treatment in Older Men

|New England Journal of Medicine|2016|864

Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug Administration

|Arthritis & Rheumatism|2002|661

Case Reports of Heart Failure after Therapy with a Tumor Necrosis Factor Antagonist

|Annals of Internal Medicine|2003|459

Life‐threatening histoplasmosis complicating immunotherapy with tumor necrosis factor α antagonists infliximab and etanercept

|Arthritis & Rheumatism|2002|448